Knockout thousands of genes - All at once
The discovery of
CRISPR-Cas9 genome editing has provided a novel and highly efficient way to probe gene function through the generation of gene knockouts.
VIDEO Our CRISPR Screening Service
Horizon offers comprehensive CRISPR screening service using a high performance vector system. The new all-in one vector system offers significantly improved performance in a rapid workflow. Our optimized CRISPR-Cas9 screening platform, sophisticated bioinformatics pipeline and multiple off-the-shelf and custom libraries allow us to design the most appropriate workflow for your screening project to provide you with data of exceptional quality.
Learn how CRISPR-Cas9 screening is going to revolutionize drug discovery Use our CRISPR screening service to:
Identify and prioritize drug targets
Find genes required for cell viability, drug sensitivity or resistance
Support patient stratification
Identify targets or pathways for potential combination therapies
CRISPR Screening Platform
Horizon can provide complete workflows for CRISPR-Cas9 knockout screens, from cell line selection and optimisation through to bioinformatics analysis of the screen results.
Turnaround time: 14-20 weeks
Deliverables: Data in raw and analysed form and a final report containing experimental details and hit nominations
Select one of our
off-the shelf sgRNA libraries or have us design a custom library!
Cell surface, Signalling & Metabolic
Deubiquitinases & Drug Targets
Kinases & DNA Damage Response
Epigenetics & Autophagy
GeCKOv2 whole genome library
Request more information Learn more about our ResponderSCREEN platform Case study: Whole genome CRISPR-Cas9 resistance screen in A375 melanoma cells
Purpose: A proof of concept study to identify resistance factors against a BRAF kinase inhibitor Vemurafenib (PLX-4032) in A375 melanoma cells that carry a BRAF V600E gain-of-function mutation.
GeCKO v2 knockout library: 6 sgRNAs against 19,050 genes (Sanjana et al., 2014)
Pooled-based approach: lentivirus transduction of the library into cells with antibiotic selection
Treatment of the edited cell population with Vemurafenib for 14 days
Cell pellet collection and sample preparation
Next-generation sequencing and data analysis using an adapted MAGeCK workflow
Highest ranking genes were
MED12, NF1, CUL3, NF2, TADA2B and TADA1, which are known to confer resistance to Vemurafenib. Additional hits include members of the STAGA histone acetyl transferase complex (
TAFL5/PAF65b) and the Mediator complex ( MED23).
Figure 1. Ranking of the hits of the screen by MAGeCK algorithm Download the complete application note Seven must-read CRISPR screening papers